Boardroom Alpha
Start trial
Boardroom Alpha
CI · Additional Proxy Materials (DEFA14A) · Filed March 13, 2026

Cigna Group — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 13, 2026
Ticker
CI
Accession
0001140361-26-009400
Cigna Group on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

The Cigna Group board backs all director nominees and executive compensation, and opposes the written-consent shareholder proposal.

About Cigna Group
Market cap
$72.1B
1Y TSR
−8.3%
3Y TSR
+3.8%
Board grade
B
Sector
Healthcare
CEO
Brian C Evanko
Last annual meeting: Apr 22, 2026 · View full Cigna Group profile →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.   )

Filed by the Registrant ☒

Filed by a Party other than the Registrant  ☐

Check the appropriate box:

☐ Preliminary Proxy Statement
   
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
   
☐ Definitive Proxy Statement
   
☒ Definitive Additional Materials
   
☐ Soliciting Material under § 240.14a-12

The Cigna Group
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒ ​No fee required


☐ ​Fee paid previously with preliminary materials


☐ ​Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 Your Vote Counts!  *Please check the meeting materials for any special requirements for meeting attendance.  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V83626-P42812-Z91840  THE CIGNA GROUP C/O PROXY SERVICES  P.O. BOX 9142  FARMINGDALE, NY 11735  The Cigna Group  2026 Annual Meeting  Vote by April 21, 2026 11:59 p.m. ET or at the meeting  You invested in The Cigna Group and it’s time to vote!  You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the  availability of proxy materials for the shareholder meeting to be held on April 22, 2026.  Get informed before you vote.  View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the materials by  requesting such materials prior to April 8, 2026. If you would like to request a copy of the materials for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com; (2) call 1-800-579-1639; or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or an email copy.  Vote virtually at the meeting*  April 22, 2026  11:00 a.m. ET  Virtually at: www.virtualshareholdermeeting.com/CI2026 
 
 Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT.  This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote on these important matters. The proxy materials are available to you on the Internet. You may view these materials online at www.proxyvote.com or request a paper or an email copy (see reverse side). We encourage you to access and review all of the important information contained in the proxy materials before voting.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  1. Election of Directors:  1a. David M. Cordani  For  1b.  Brian C. Evanko  For  1c.  Eric J. Foss  For  1d.  Neesha Hathi  For  1e.  Michael J. Hennigan  For  1f.  George Kurian  For  1g.  Kathleen M. Mazzarella  For  1h.  Mark B. McClellan, M.D., Ph.D.  For  1i.  Philip O. Ozuah, M.D., Ph.D.  For  1j.  Kimberly A. Ross  For  1k.  Eric C. Wiseman  For  1l.  Donna F. Zarcone  For  2. Advisory approval of executive compensation  For  3. Ratification of the appointment of PricewaterhouseCoopers LLP as The Cigna Group’s independent registered public accounting firm for 2026  For  4. Shareholder Proposal — Shareholder Right to Act by Written Consent  Against  Note: Such other business as may properly come before the meeting or any postponements or adjournments thereof  Our board has fixed the close of business on February 23, 2026 as the record date for the determination of shareholders entitled to notice of, and to vote at, the meeting and any adjournments thereof. A list of shareholders will be made available to shareholders during ordinary business hours for a period of at least ten days ending on the day before the meeting date at www.virtualshareholdermeeting.com/CI2026.  Voting Items  Board Recommends  V83627-P42812-Z91840 
 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting ForecastSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Cigna Group (CI)

Continue researching
Reference

Frequently asked questions

When did Cigna Group file this DEFA14A?
Cigna Group (CI) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 13, 2026. The accession number assigned by EDGAR is 0001140361-26-009400.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
The Cigna Group board backs all director nominees and executive compensation, and opposes the written-consent shareholder proposal. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Cigna Group's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Cigna Group has filed under CIK 1739940, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer